Price Alert

Arcutis Biotherapeutics I... (ARQT)

NASDAQ: ARQT · Real-Time Price · USD

16.45

0.47 (2.94%)

At close: Aug 15, 2025, 12:34 PM

Arcutis Biotherapeutics Statistics

Share Statistics

Arcutis Biotherapeutics has 119.2M shares outstanding. The number of shares has increased by 1.98% in one year.

Shares Outstanding	119.2M
Shares Change (YoY)	1.98%
Shares Change (QoQ)	0.48%
Owned by Institutions (%)	99.19%
Shares Floating	105.42M
Failed to Deliver (FTD) Shares	47
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 17.27M, so 14.48% of the outstanding shares have been sold short.

Short Interest	17.27M
Short % of Shares Out	14.48%
Short % of Float	17.91%
Short Ratio (days to cover)	10.04

Valuation Ratios

The PE ratio is -12.03 and the forward PE ratio is 64.07. Arcutis Biotherapeutics's PEG ratio is 0.17.

PE Ratio	-12.03
Forward PE	64.07
PS Ratio	8.57
Forward PS	3.9
PB Ratio	10.7
P/FCF Ratio	-15
PEG Ratio	0.17

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Arcutis Biotherapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.7.

Current Ratio	4.15
Quick Ratio	3.97
Debt / Equity	0.7
Debt / EBITDA	-1.01
Debt / FCF	-0.98
Interest Coverage	-4.73

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$574.68K
Profits Per Employee	$-409.47K
Employee Count	342
Asset Turnover	0.56
Inventory Turnover	1.32

Taxes

Income Tax	647K
Effective Tax Rate	-0.46%

Stock Price Statistics

The stock price has increased by 49.53% in the last 52 weeks. The beta is 1.84, so Arcutis Biotherapeutics's price volatility has been higher than the market average.

Beta	1.84
52-Week Price Change	49.53%
50-Day Moving Average	14.28
200-Day Moving Average	13.45
Relative Strength Index (RSI)	51.21
Average Volume (20 Days)	1,856,488

Income Statement

In the last 12 months, Arcutis Biotherapeutics had revenue of 196.54M and earned -140.04M in profits. Earnings per share was -1.16.

Revenue	196.54M
Gross Profit	177.41M
Operating Income	-128.4M
Net Income	-140.04M
EBITDA	-109.63M
EBIT	-112.22M
Earnings Per Share (EPS)	-1.16

Full Income Statement

Balance Sheet

The company has 71.33M in cash and 110.58M in debt, giving a net cash position of -39.25M.

Cash & Cash Equivalents	71.33M
Total Debt	110.58M
Net Cash	-39.25M
Retained Earnings	-1.12B
Total Assets	352.43M
Working Capital	228.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -112.16M and capital expenditures -143K, giving a free cash flow of -112.3M.

Operating Cash Flow	-112.16M
Capital Expenditures	-143K
Free Cash Flow	-112.3M
FCF Per Share	-0.93

Full Cash Flow Statement

Margins

Gross margin is 90.27%, with operating and profit margins of -65.33% and -71.25%.

Gross Margin	90.27%
Operating Margin	-65.33%
Pretax Margin	-70.92%
Profit Margin	-71.25%
EBITDA Margin	-55.78%
EBIT Margin	-65.33%
FCF Margin	-57.14%

Dividends & Yields

ARQT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ARQT is $19, which is 33.9% higher than the current price. The consensus rating is "Buy".

Price Target	$19
Price Target Difference	33.9%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.19
Piotroski F-Score	4